Light-based test of blood and urine to tell kidney diseases apart
Tests Raman spectroscopy on blood and urine samples from people with kidney diseases.
Plain-language title generated from the registry record
Registry title: Raman Spectroscopy Diagnosis of Kidney Diseases
Key facts
- Where
- Jinan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with kidney disease confirmed by kidney biopsy: IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy or focal segmental glomerulosclerosis, who have not yet had hormone or immune-suppressing treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, or focal segmental glomerulosclerosis, confirmed by kidney biopsy
- Earlier treatment
- No hormone and/or immunosuppressive therapy before the kidney biopsy
Main reasons for not taking part
- Membranous nephropathy caused by another condition, such as lupus, viral hepatitis, drugs or toxins
- Severe infection with high white blood cell count
- Severe heart disease: heart failure grade 3 or above, or arrhythmias
- Active hepatitis, AIDS or syphilis
- Known or suspected tumor
Read by machine on 9 November 2026.
Where in China
- Shandong Second Medical University. No.7166 Baotong West Street, Weifang, Shandong, 261053, China.Jinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zunsong Wang
- Trial code
- NCT06760845
- Record updated
- 7 January 2025
- Original description
This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis the Nephrology Department of Qianfoshan Hospital in Shandong Province, through renal biopsy. These samples will be scanned using a Raman spect to obtain Raman spectral data. The scattering peaks in the Raman spectra will be analyzed using Origin software for Gaussian curve fitting. The position of the peaks will used to query relevant literature to identify the corresponding chemical bonds and confirm the presence of compounds.Read full original descriptionShow less
Research on Raman Spectroscopy Detection Technology in Kidney Disease Diagnosis
This research plan, from January 2021 to December 2024, aims to collect serum and morning urine from patients diagnosed with IgA nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis the Nephrology Department of Qianfoshan Hospital in Shandong Province, through renal biopsy. These samples will be scanned using a Raman spect to obtain Raman spectral data. The scattering peaks in the Raman spectra will be analyzed using Origin software for Gaussian curve fitting. The position of the peaks will used to query relevant literature to identify the corresponding chemical bonds and confirm the presence of compounds.
The intensity and area of the chemical substance peaks in the Raman will be calculated and used to plot calibration curves, thereby establishing a quantitative analysis equation. This equation will be used to accurately calculate the concentration of each analyte in serum and urine samples. Based on the average concentration data for each patient group, multivariate analysis methods, such as principal component analysis (PCA) and Mahalanis distance discriminant model, will be used to classify and predict the disease types.
The preliminary data for this study comes from the Nephrology Department ofianfoshan Hospital, where different types of glomerular diseases have been pathologically classified using tools such as light microscopy, electron microscopy, and immunoforescence microscopy. By combining Raman spectroscopy technology and statistical analysis, this study aims to establish a non-invasive and efficient diagnostic tool to assist in the of kidney diseases and predict treatment outcomes.
Inclusion: Age 18 years or older; Patients diagnosed with IgA nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy; Patients who have not received hormone and/or immunosup therapy before the renal biopsy.
Exclusion: Presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),/infections (viral hepatitis), drugs or toxins, etc; Severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias; Infect diseases: active phase of various types of hepatitis, AIDS, syphilis, etc; Severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09/L); Evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor; Patients with incomplete data or missed diagnosis.